Addition of interleukin 12 to low dose interleukin 2 treatment improves antitumor efficacy in vivo.

Abstract

Interleukin 12 (IL-12) enhances lysis mediated by NK- and lymphokine activated killer (LAK) cells. It also causes proliferation of IL-2 stimulated T and NK cells in vitro. For these IL-2 complementing properties murine pulmonary metastases of a coloncarcinoma line were treated with IL-12 and IL-2 or with the individual agents. Results were compared to sham… (More)

Topics

Cite this paper

@article{Leder1995AdditionOI, title={Addition of interleukin 12 to low dose interleukin 2 treatment improves antitumor efficacy in vivo.}, author={Gerhard Leder and M. L. S. Oppenheim and Michael T. Rosenstein and Michael T Lotze and Hans G{\"u}nter Beger}, journal={Zeitschrift fur Gastroenterologie}, year={1995}, volume={33 9}, pages={499-502} }